2010 Help me understand this report
Can patient-reported kidney cancer–specific symptoms at baseline serve as an indicator for median progression-free and overall survival in sorafenib-refractory metastatic renal cell carcinoma?
Search citation statements
Paper Sections
Select...
1
Citation Types
0
1
0
Year Published
2011
2011
Publication Types
Select...
1
Relationship
0
1
Authors
Journals
Cited by 1 publication
(1 citation statement)
References 0 publications
0
1
0
“…In a separate phase II study of axitinib treatment of sorafenib-resistant patients, longer median PFS and OS times were associated with more favorable FKSI-15 and FKSI-DRS scores at baseline [37].…”
Section: Axitinibmentioning
confidence: 99%
“…In a separate phase II study of axitinib treatment of sorafenib-resistant patients, longer median PFS and OS times were associated with more favorable FKSI-15 and FKSI-DRS scores at baseline [37].…”
Section: Axitinibmentioning
confidence: 99%
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
Copyright © 2025 scite LLC. All rights reserved.
Made with 💙 for researchers
